Form D · Biotechnology
STABILUX BIOSCIENCES, INC.
Ann Arbor, MI · CIK 0002023675
Offering snapshot reported May 16, 2024 · SEC filing
- Reported sold
- $554K Offering amount: $3M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 24, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 16, 2024 | Initial | $554,381 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-513524
Source: Form D, filed May 16, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Ehlert | Director |
| Jonathan Leinonen | Director, Executive |
| Michael Mortlock | Executive |
| John Ransom | Director |
| Steve Tokarz | Director, Executive |
| Yoke Khin Yap | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
600 S Wagner Road
Ann Arbor, MI, 48103
Ann Arbor, MI, 48103